FDA Approves Humira Biosimilar Hyrimoz for Treatment of IBD, Other Conditions
News
The U.S. Food and Drug Administration (FDA) approved Hyrimoz (adalimumab-adaz, by Sandoz), a biosimilar to AbbVie’s Humira (adalimumab) for the treatment of Crohn’s disease (CD) in adults and ulcerative colitis (UC). A biosimilar ... Read more